HRP20201574T1 - Supstituirani nikotinimidni inhibitori btk, njihova priprava i upotreba u liječenju raka, upale i autoimunih bolesti - Google Patents
Supstituirani nikotinimidni inhibitori btk, njihova priprava i upotreba u liječenju raka, upale i autoimunih bolesti Download PDFInfo
- Publication number
- HRP20201574T1 HRP20201574T1 HRP20201574TT HRP20201574T HRP20201574T1 HR P20201574 T1 HRP20201574 T1 HR P20201574T1 HR P20201574T T HRP20201574T T HR P20201574TT HR P20201574 T HRP20201574 T HR P20201574T HR P20201574 T1 HRP20201574 T1 HR P20201574T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- nicotinamide
- phenoxyphenyl
- acryloylpiperazin
- cancer
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- MZPVEMOYADUARK-UHFFFAOYSA-N 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(C2CCN(CC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 MZPVEMOYADUARK-UHFFFAOYSA-N 0.000 claims 1
- HKODXZQCALAKRP-RMKNXTFCSA-N CN(C/C=C/C(=O)N1CCN(CC1)C1=NC(=C(C(=O)N)C=C1)C1=CC=C(C=C1)OC1=CC=CC=C1)C Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)C1=NC(=C(C(=O)N)C=C1)C1=CC=C(C=C1)OC1=CC=CC=C1)C HKODXZQCALAKRP-RMKNXTFCSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- FVFNTQTXHXLUCG-UHFFFAOYSA-N NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C FVFNTQTXHXLUCG-UHFFFAOYSA-N 0.000 claims 1
- RXLBSUXDQSYOQK-UHFFFAOYSA-N NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(cc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C RXLBSUXDQSYOQK-UHFFFAOYSA-N 0.000 claims 1
- ALCPIQJGNIFEEW-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(F)cc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(F)cc2)cc1)N1CCN(CC1)C(=O)C=C ALCPIQJGNIFEEW-UHFFFAOYSA-N 0.000 claims 1
- FOVPGEGKCVVOCG-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(cc2)C#N)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccc(cc2)C#N)cc1)N1CCN(CC1)C(=O)C=C FOVPGEGKCVVOCG-UHFFFAOYSA-N 0.000 claims 1
- YSLHZFWPYAMITN-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2cccc(F)c2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2cccc(F)c2)cc1)N1CCN(CC1)C(=O)C=C YSLHZFWPYAMITN-UHFFFAOYSA-N 0.000 claims 1
- HSJHKGOOSPVBOE-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)c(F)c1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)c(F)c1)N1CCN(CC1)C(=O)C=C HSJHKGOOSPVBOE-UHFFFAOYSA-N 0.000 claims 1
- YRXXJFYRLCXWSW-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCCN(C1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCCN(C1)C(=O)C=C YRXXJFYRLCXWSW-UHFFFAOYSA-N 0.000 claims 1
- FFOQNEVDIRMUML-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(C1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(C1)C(=O)C=C FFOQNEVDIRMUML-UHFFFAOYSA-N 0.000 claims 1
- AUZUWAWZXHHHRK-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)S(=O)(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)S(=O)(=O)C=C AUZUWAWZXHHHRK-UHFFFAOYSA-N 0.000 claims 1
- QTBYHUSOXPOMAU-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)C(=O)C=C QTBYHUSOXPOMAU-UHFFFAOYSA-N 0.000 claims 1
- TVVGIVUDWNGTBO-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)S(=O)(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)N1CCN(CC1)S(=O)(=O)C=C TVVGIVUDWNGTBO-UHFFFAOYSA-N 0.000 claims 1
- VGYWZKPHSUBBSA-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1F)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1F)N1CCN(CC1)C(=O)C=C VGYWZKPHSUBBSA-UHFFFAOYSA-N 0.000 claims 1
- LQTWOAKAPZKRHG-UHFFFAOYSA-N NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2F)cc1)N1CCN(CC1)C(=O)C=C Chemical compound NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2F)cc1)N1CCN(CC1)C(=O)C=C LQTWOAKAPZKRHG-UHFFFAOYSA-N 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (4)
1. Spoj, naznačen time što ga se bira iz skupine koju čine:
6-(1-akriloilpiperidin-4-il)-2-(4-fenoksifenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(4-fenoksifenil)nikotinamid;
[image]
6-(1-akriloilpirolidin-3-il)-2-(4-fenoksifenil)nikotinamid;
[image]
6-(1-akriloilpiperidin-3-il)-2-(4-fenoksifenil)nikotinamid;
[image]
(E)-6-(4-(4-(dimetilamino)but-2-enoil)piperazin-1-il)-2-(4-fenoksifenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(4-(4-cijanofenoksi)fenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(4-(3-fluorfenoksi)fenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(3-fluor-4-fenoksifenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(4-(4-fluorfenoksi)fenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(4-(2-fluorfenoksi)fenil)nikotinamid;
[image]
6-(4-akriloilpiperazin-1-il)-2-(2-fluor-4-fenoksifenil)nikotinamid;
[image]
5-(1-akriloilpiperidin-4-il)-4′-fenoksibifenil-2-karboksamid;
[image]
5-(4-akriloilpiperazin-1-il)-4′-fenoksibifenil-2-karboksamid;
[image]
2-(4-fenoksifenil)-6-(4-(vinilsulfonil)piperazin-1-il)nikotinamid;
[image]
2-(4-fenoksifenil)-6-(1-(vinilsulfonil)piperidin-4-il)nikotinamid;
[image]
ili njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili
[image]
.
3. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili patentnim zahtjevom 2, ili njegovu farmaceutski prihvatljivu sol.
4. Farmaceutski pripravak namijenjen upotrebi u liječenju raka, kronične upale, ili autoimune bolesti kod sisavca, naznačen time što sadrži spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili patentnog zahtjeva 2, ili njegovu farmaceutski prihvatljivu sol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884958P | 2013-09-30 | 2013-09-30 | |
| CN201310485048 | 2013-10-16 | ||
| EP14848083.3A EP3052476B1 (en) | 2013-09-30 | 2014-09-29 | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
| PCT/US2014/058084 WO2015048662A2 (en) | 2013-09-30 | 2014-09-29 | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201574T1 true HRP20201574T1 (hr) | 2020-12-11 |
Family
ID=72422342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201574TT HRP20201574T1 (hr) | 2013-09-30 | 2020-10-05 | Supstituirani nikotinimidni inhibitori btk, njihova priprava i upotreba u liječenju raka, upale i autoimunih bolesti |
Country Status (6)
| Country | Link |
|---|---|
| DK (1) | DK3052476T3 (hr) |
| ES (1) | ES2822586T3 (hr) |
| HR (1) | HRP20201574T1 (hr) |
| HU (1) | HUE050771T2 (hr) |
| LT (1) | LT3052476T (hr) |
| PT (1) | PT3052476T (hr) |
-
2014
- 2014-09-29 ES ES14848083T patent/ES2822586T3/es active Active
- 2014-09-29 DK DK14848083.3T patent/DK3052476T3/da active
- 2014-09-29 HU HUE14848083A patent/HUE050771T2/hu unknown
- 2014-09-29 PT PT148480833T patent/PT3052476T/pt unknown
- 2014-09-29 LT LTEP14848083.3T patent/LT3052476T/lt unknown
-
2020
- 2020-10-05 HR HRP20201574TT patent/HRP20201574T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3052476T3 (da) | 2020-09-14 |
| NZ718073A (en) | 2021-04-30 |
| ES2822586T3 (es) | 2021-05-04 |
| LT3052476T (lt) | 2020-10-26 |
| PT3052476T (pt) | 2020-10-09 |
| HUE050771T2 (hu) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502074A1 (en) | Sustained release dosage forms for a jak1 inhibitor | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| SMT201500194B (it) | Co-cristalli con l-prolina e acido citrico di (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorofenil) tiofen-2-il)metil)-4-metilfenil)-6-(idrossimetil) tetraidro-2H-piran-3,4,5-triolo | |
| AR086913A1 (es) | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas | |
| HRP20190793T1 (hr) | Spojevi dimetilbenzojeve kiseline | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| RS54608B1 (en) | CGRP RECEPTOR ANTAGONITY | |
| EA201400553A1 (ru) | Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида | |
| EA201692465A1 (ru) | Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида | |
| EA201291421A1 (ru) | Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли | |
| DK3556350T3 (da) | Farmaceutisk præparat indeholdende et antiviralt aktivt dihydroquinazolinderivat med s-konfiguration i 4-stillingen | |
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| CY1119687T1 (el) | Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης | |
| NO2020032I1 (no) | Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| HRP20200686T1 (hr) | Derivati 2,3-dihidro-1h-inden-1-ona kao antagonisti orfan receptora gama povezanog s retinoinskom kiselinom (ror gama) za liječenje multiple skleroze | |
| HRP20201574T1 (hr) | Supstituirani nikotinimidni inhibitori btk, njihova priprava i upotreba u liječenju raka, upale i autoimunih bolesti | |
| EA201691231A1 (ru) | Фармацевтические лекарственные формы | |
| CL2014001247A1 (es) | Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion. | |
| BR112017012136A2 (pt) | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr | |
| SI2958552T1 (sl) | Farmacevtski sestavek, ki sestoji iz n-(3-kloro-4-(3-fluorobenziloksi) fenil)-6-(5(((2-(metilsulfonil)etil)amino)metil)-2-furil)kinazolin-4- amina ali farmacevtsko sprejemljive soli, solvata ali njegove solvirane soli | |
| HK1221225A1 (zh) | -二氨基吡唑激酶抑制劑的藥學上可接受的鹽 | |
| DK3057580T3 (da) | Farmaceutiske administrationsformer indeholdende natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat | |
| TH1601002081A (th) | รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต | |
| EA201301190A1 (ru) | Фармацевтическая композиция эрлотиниба |